Australian Nuclear Science and Technology Organisation (ANSTO)

Regulatory activities for this sponsor.

2 result(s) found, displaying 1 to 2

AusPAR: Lutetium (177Lu) chloride

16 September 2022

Australian Public Assessment Report (AusPAR)

AusPAR for Lutetium (177Lu) chloride (lutetium (177Lu) chloride) for the treatment of non-resectable or metastatic neuroendocrine tumours expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.
Lutetium (177Lu) Chloride

21 January 2022

Prescription medicine decision summary

ANSTO Lutetium (177Lu) chloride (lutetium (177 Lu) chloride) is approved to treat non resectable or metastatic neuroendocrine tumours.